Tilray Expands Medical Cannabis Portfolio in Portugal

LOS ANGELES- Tilray Brands, Inc.  has announced a new achievement in its European medical cannabis operations. The company received approval for its new product, Tilray Solução Oral THC10, in Portugal. This follows earlier approvals for Tilray Medical’s whole flower THC 18 and another cannabis extract in the country.

Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International, expressed pride in the approval, highlighting its significance for patient care in Portugal. She noted that this development aligns with Tilray’s commitment to providing high-quality cannabis products and expanding access for patients with specific medical needs.

Tilray Medical, which offers a range of EU-GMP certified cannabis products, operates in over 20 countries. The company’s mission is to enhance patient care through safe and regulated cannabis options, supporting a broad spectrum of medical needs globally.